RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study

Landriscina,Matteo; Natalicchio,Maria  Iole; Lamacchia,Olga; Conserva,Antonella; Piscazzi,Annamaria; Ciampolillo,Anna; Zingrillo,Matteo; Pennella,Antonio; Bufo,Pantaleo; Vita,Giulia; Antonetti,Raffaele; Maiorano,Eugenio; Giorgino,Francesco; Cignarelli,Mauro

doi:10.3892/ol.2015.3386

RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study

Authors:
- Matteo Landriscina
- Maria Iole Natalicchio
- Olga Lamacchia
- Antonella Conserva
- Annamaria Piscazzi
- Anna Ciampolillo
- Matteo Zingrillo
- Antonio Pennella
- Pantaleo Bufo
- Giulia Vita
- Raffaele Antonetti
- Eugenio Maiorano
- Francesco Giorgino
- Mauro Cignarelli
View Affiliations

Affiliations: Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Foggia I-71100, Italy, Molecular Biology Laboratory, Riuniti Hospital, Foggia, Foggia I-71100, Italy, Endocrinology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Foggia I-71100, Italy, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Bari I-70124, Italy, Azienda Sanitaria Locale Foggia, Foggia, Foggia I-71100, Italy, Pathology Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Foggia I-71100, Italy, Pathology Unit, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza I-85028, Italy, Section of Pathology, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Bari I-70124, Italy
Published online on: June 17, 2015 https://doi.org/10.3892/ol.2015.3386
Pages: 1875-1881

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are contrasting views on whether familial non-medullary thyroid carcinomas (FNMTCs) are characterized by aggressive behavior, and limited evidence exists on the prognostic value of BRAF and RAS mutations in these tumors. Thus, in the present study, clinicopathological features were analyzed in 386 non‑medullary thyroid carcinomas (NMTCs), subdivided in 82 familial and 304 sporadic cases. Furthermore, the RAS and BRAF mutational statuses were investigated in a subgroup of 34 FNMTCs to address their clinical and biological significance. The results demonstrated that, compared with sporadic NMTCs, FNMTCs are characterized by significantly higher rates of multicentricity and bilaterality and are more frequently associated with chronic autoimmune thyroiditis. Notably, a statistically significant difference in the rates of multicentricity was observed by subgrouping familial tumors according to the number of relatives involved; those with ≥3 affected relatives were more likely to be multicentric. Furthermore, the FNMTC cohort exhibited higher rates of tumors >4 cm in size with extrathyroidal or lymph node involvement. However, no significant difference was observed. Similarly, no differences were observed with respect to the age of onset or the patient outcome. The mutational profiling exhibited a rate of 58.8% for BRAF V600E mutations in familial tumors, which is at the upper limit of the mutational frequency observed in historical series of sporadic thyroid cancer. A high rate of NRAS mutations (17.6%) was also observed, mostly in the follicular variant histotype. Notably, compared with BRAF/RAS‑wild type FNMTCs, the familial carcinomas bearing BRAF or NRAS mutations exhibited slightly higher rates of bilaterality and multicentricity, in addition to increased frequency of locally advanced stage or lymph node involvement. The present data support the theory that FNMTCs are characterized by clinicopathological features that resemble a more aggressive phenotype and suggest that RAS/BRAF mutational analysis deserves to be further evaluated as a tool for the identification of FNMTCs with a potentially unfavorable prognosis.

View Figures

View References

1	Mazeh H and Sippel RS: Familial nonmedullary thyroid carcinoma. Thyroid. 23:1049–1056. 2013. View Article : Google Scholar : PubMed/NCBI
2	Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, Treseler PA, Weier HU, Freimer N, Siperstein AE, et al: Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 128:1043–1051. 2000.
3	Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S and Shuto S: Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 26:897–902. 2002. View Article : Google Scholar : PubMed/NCBI
4	Mazeh H, Benavidez J, Poehls JL, Youngwirth L, Chen H and Sippel RS: In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid. 22:3–8. 2012. View Article : Google Scholar : PubMed/NCBI
5	Park YJ, Ahn HY, Choi HS, Kim KW, Park J and Cho BY: The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid. 22:356–362. 2012. View Article : Google Scholar : PubMed/NCBI
6	Lee YM, Yoon JH, Yi O, Sung TY, Chung KW, Kim WB and Hong SJ: Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma. J Surg Oncol. 109:168–173. 2014. View Article : Google Scholar : PubMed/NCBI
7	McDonald TJ, Driedger AA, Garcia BM, Van Uum SH, Rachinsky I, Chevendra V, Breadner D, Feinn R, Walsh SJ and Malchoff CD: Familial papillary thyroid carcinoma: A retrospective analysis. J Oncol. 2011:9487862011. View Article : Google Scholar : PubMed/NCBI
8	Maxwell EL, Hall FT and Freeman JL: Familial non-medullary thyroid cancer: A matched-case control study. Laryngoscope. 114:2182–2186. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ito Y, Kakudo K, Hirokawa M, Fukushima M, Yabuta T, Tomoda C, Inoue H, Kihara M, Higashiyama T and Uruno T: Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 145:100–105. 2009. View Article : Google Scholar : PubMed/NCBI
10	Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, et al: Clinical characteristics and outcome of familial nonmedullary thyroid cancer: A retrospective controlled study. Thyroid. 21:43–48. 2011. View Article : Google Scholar : PubMed/NCBI
11	Moses W, Weng J and Kebebew E: Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid. 21:367–371. 2011. View Article : Google Scholar : PubMed/NCBI
12	Pinto AE, Silva GL, Henrique R, Menezes FD, Teixeira MR, Leite V and Cavaco BM: Familial vs sporadic papillary thyroid carcinoma: A matched-case comparative study thening similar clinical/prognostic behaviour. Eur J Endocrinol. 170:321–327. 2014. View Article : Google Scholar : PubMed/NCBI
13	Malchoff CD and McDonald TJ: Is familial nonmedullary thyroid carcinoma more aggressive than sporadic nonmedullary thyroid carcinoma? Thyroid. 24:782–783. 2014. View Article : Google Scholar : PubMed/NCBI
14	Charkes ND: On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 16:181–186. 2006. View Article : Google Scholar : PubMed/NCBI
15	Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, et al: Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 24:6646–6656. 2005. View Article : Google Scholar : PubMed/NCBI
16	Shaha AR: TNM classification of thyroid carcinoma. World J Surg. 31:879–887. 2007. View Article : Google Scholar : PubMed/NCBI
17	Natalicchio MI, Improta G, Zupa A, Cursio OE, Stampone E, Possidente L, Teresa Gerardi AM, Vita G, Martini M, Cassano A, et al: Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. Future Oncol. 10:713–723. 2014. View Article : Google Scholar : PubMed/NCBI
18	Vriens MR, Schreinemakers JM, Suh I, Guerrero MA and Clark OH: Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol. 5:1283–1293. 2009. View Article : Google Scholar : PubMed/NCBI
19	Bauer AJ: Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer. Front Horm Res. 41:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
20	Champion KJ, Bunag C, Estep AL, Jones JR, Bolt CH, Rogers RC, Rauen KA and Everman DB: Germline mutation in BRAF codon 600 is compatible with human development: De novo p.V600G mutation identified in a patient with CFC syndrome. Clin Genet. 79:468–474. 2011. View Article : Google Scholar : PubMed/NCBI
21	Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, König R, et al: A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 42:27–29. 2010. View Article : Google Scholar : PubMed/NCBI
22	Son EJ and Nosé V: Familial follicular cell-derived thyroid carcinoma. Front Endocrinol (Lausanne). 3:612012.PubMed/NCBI
23	Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG and Fugazzola L: The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: Clinical and molecular studies. Clin Endocrinol (Oxf). 72:702–708. 2010. View Article : Google Scholar : PubMed/NCBI
24	Rotondi M, Coperchini F, Pignatti P, Sideri R, Groppelli G, Leporati P, La Manna L, Magri F, Mariotti S and Chiovato L: Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: A first step toward a differentiation between autoimmune and tumor-related inflammation? J Clin Endocrinol Metab. 98:308–313. 2013. View Article : Google Scholar : PubMed/NCBI
25	Bozec A, Lassalle S, Hofman V, Ilie M, Santini J and Hofman P: The thyroid gland: A crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem. 17:3449–3461. 2010.
26	Medici M, Porcu E, Pistis G, Teumer A, Brown SJ, Jensen RA, Rawal R, Roef GL, Plantinga TS, Vermeulen SH, et al: Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease. PLoS Genet. 10:e10041232014. View Article : Google Scholar : PubMed/NCBI
27	Handkiewicz-Junak D, Czarniecka A and Jarzab B: Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol. 322:8–28. 2010. View Article : Google Scholar : PubMed/NCBI
28	Jang EK, Song DE, Sim SY, Kwon H, Choi YM, Jeon MJ, Han JM, Kim WG, Kim TY, Shong YK, et al: NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma. Thyroid. 24:1275–1281. 2014. View Article : Google Scholar : PubMed/NCBI
29	Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi Cu, et al: The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 97:4390–4398. 2012. View Article : Google Scholar : PubMed/NCBI
30	Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, et al: Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab. 98:3702–3712. 2013. View Article : Google Scholar
31	Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, Pięciak L and Góźdź S: The BRAF(V600E) mutation in papillary thyroid microcarcinoma: Does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf). 80:899–904. 2014. View Article : Google Scholar : PubMed/NCBI